APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

End-Stage Renal Disease (ESRD) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global End-Stage Renal Disease (ESRD) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173988170319 December 2025187 pages

Choose your research edition.

Industry ResearchEnd-Stage Renal Disease (ESRD) Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal End-Stage Renal Disease (ESRD) Drugs Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal End-Stage Renal Disease (ESRD) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal End-Stage Renal Disease (ESRD) Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal End-Stage Renal Disease (ESRD) Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global End-Stage Renal Disease (ESRD) Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for End-Stage Renal Disease (ESRD) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for End-Stage Renal Disease (ESRD) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for End-Stage Renal Disease (ESRD) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for End-Stage Renal Disease (ESRD) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of End-Stage Renal Disease (ESRD) Drugs include Novartis AG, Merck & Co Inc, VESSL Therapeutics Ltd, Prolong Pharmaceuticals LLC and CTI BioPharma Corp, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global End-Stage Renal Disease (ESRD) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of End-Stage Renal Disease (ESRD) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents End-Stage Renal Disease (ESRD) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the End-Stage Renal Disease (ESRD) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

End-Stage Renal Disease (ESRD) Drugs Segment by Company

Novartis AG

Merck & Co Inc

VESSL Therapeutics Ltd

Prolong Pharmaceuticals LLC

CTI BioPharma Corp

End-Stage Renal Disease (ESRD) Drugs Segment by Type

Sanguinate

Tesidolumab

Calcium Succinate

Mk-3866

Pacritinib

Others

End-Stage Renal Disease (ESRD) Drugs Segment by Application

ICU

Hospital

Clinic

Others

End-Stage Renal Disease (ESRD) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global End-Stage Renal Disease (ESRD) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of End-Stage Renal Disease (ESRD) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of End-Stage Renal Disease (ESRD) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the End-Stage Renal Disease (ESRD) Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of End-Stage Renal Disease (ESRD) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of End-Stage Renal Disease (ESRD) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of End-Stage Renal Disease (ESRD) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. End-Stage Renal Disease (ESRD) Drugs Industry Trends Table 2. End-Stage Renal Disease (ESRD) Drugs Industry Drivers Table 3. End-Stage Renal Disease (ESRD) Drugs Industry Opportunities and Challenges Table 4. End-Stage Renal Disease (ESRD) Drugs Industry Restraints Table 5. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global End-Stage Renal Disease (ESRD) Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Manufacturers Table 9. Global End-Stage Renal Disease (ESRD) Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global End-Stage Renal Disease (ESRD) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global End-Stage Renal Disease (ESRD) Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global End-Stage Renal Disease (ESRD) Drugs Manufacturers, Product Type & Application Table 13. Global End-Stage Renal Disease (ESRD) Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global End-Stage Renal Disease (ESRD) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Sanguinate Table 17. Major Manufacturers of Tesidolumab Table 18. Major Manufacturers of Calcium Succinate Table 19. Major Manufacturers of Mk-3866 Table 20. Major Manufacturers of Pacritinib Table 21. Major Manufacturers of Others Table 22. Global End-Stage Renal Disease (ESRD) Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2026) & (K Units) Table 24. Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2027-2032) & (K Units) Table 25. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type (2021-2026) Table 26. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type (2027-2032) Table 27. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021-2026) & (K Units) Table 29. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2027-2032) & (K Units) Table 30. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Type (2021-2026) Table 31. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of ICU Table 33. Major Manufacturers of Hospital Table 34. Major Manufacturers of Clinic Table 35. Major Manufacturers of Others Table 36. Global End-Stage Renal Disease (ESRD) Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2026) & (K Units) Table 38. Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2027-2032) & (K Units) Table 39. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2021-2026) Table 40. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2027-2032) Table 41. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021-2026) & (K Units) Table 43. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2027-2032) & (K Units) Table 44. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Application (2021-2026) Table 45. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Application (2027-2032) Table 46. Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global End-Stage Renal Disease (ESRD) Drugs Sales by Region (2021-2026) & (K Units) Table 48. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Region (2021-2026) Table 49. Global End-Stage Renal Disease (ESRD) Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global End-Stage Renal Disease (ESRD) Drugs Sales Forecasted Market Share by Region (2027-2032) Table 51. North America End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2026) & (K Units) Table 53. North America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2027-2032) & (K Units) Table 54. Europe End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2026) & (K Units) Table 56. Europe End-Stage Renal Disease (ESRD) Drugs Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Sales by Country (2027-2032) & (K Units) Table 63. Global End-Stage Renal Disease (ESRD) Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 65. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 66. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region (2021-2026) Table 67. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region (2027-2032) Table 68. Novartis AG Company Information Table 69. Novartis AG Business Overview Table 70. Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Novartis AG End-Stage Renal Disease (ESRD) Drugs Product Portfolio Table 72. Novartis AG Recent Development Table 73. Merck & Co Inc Company Information Table 74. Merck & Co Inc Business Overview Table 75. Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Product Portfolio Table 77. Merck & Co Inc Recent Development Table 78. VESSL Therapeutics Ltd Company Information Table 79. VESSL Therapeutics Ltd Business Overview Table 80. VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Product Portfolio Table 82. VESSL Therapeutics Ltd Recent Development Table 83. Prolong Pharmaceuticals LLC Company Information Table 84. Prolong Pharmaceuticals LLC Business Overview Table 85. Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Product Portfolio Table 87. Prolong Pharmaceuticals LLC Recent Development Table 88. CTI BioPharma Corp Company Information Table 89. CTI BioPharma Corp Business Overview Table 90. CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Product Portfolio Table 92. CTI BioPharma Corp Recent Development Table 93. Key Raw Materials Table 94. Raw Materials Key Suppliers Table 95. End-Stage Renal Disease (ESRD) Drugs Distributors List Table 96. End-Stage Renal Disease (ESRD) Drugs Customers List Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. End-Stage Renal Disease (ESRD) Drugs Product Image Figure 2. Global End-Stage Renal Disease (ESRD) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global End-Stage Renal Disease (ESRD) Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global End-Stage Renal Disease (ESRD) Drugs Sales (2021-2032) & (K Units) Figure 5. Global End-Stage Renal Disease (ESRD) Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 End-Stage Renal Disease (ESRD) Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Sanguinate Image Figure 9. Tesidolumab Image Figure 10. Calcium Succinate Image Figure 11. Mk-3866 Image Figure 12. Pacritinib Image Figure 13. Others Image Figure 14. Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type (2021-2032) Figure 17. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Type (2021-2032) Figure 20. ICU Image Figure 21. Hospital Image Figure 22. Clinic Image Figure 23. Others Image Figure 24. Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2021-2032) Figure 27. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Application (2021-2032) Figure 30. North America End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Country (2021-2032) Figure 32. U.S. End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Country (2021-2032) Figure 37. Germany End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Country (2021-2032) Figure 44. China End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Country (2021-2032) Figure 52. Brazil End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global End-Stage Renal Disease (ESRD) Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Figure 63. North America End-Stage Renal Disease (ESRD) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Europe End-Stage Renal Disease (ESRD) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific End-Stage Renal Disease (ESRD) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. End-Stage Renal Disease (ESRD) Drugs Value Chain Figure 71. Manufacturing Cost Structure Figure 72. End-Stage Renal Disease (ESRD) Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Sanguinate
  • Tesidolumab
  • Calcium Succinate
  • Mk-3866
  • Pacritinib
  • Others
Applications
  • ICU
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Merck & Co Inc
  • VESSL Therapeutics Ltd
  • Prolong Pharmaceuticals LLC
  • CTI BioPharma Corp

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global End-Stage Renal Disease (ESRD) Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global End-Stage Renal Disease (ESRD) Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global End-Stage Renal Disease (ESRD) Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global End-Stage Renal Disease (ESRD) Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global End-Stage Renal Disease (ESRD) Drugs Market Dynamics
  1. 2.1 End-Stage Renal Disease (ESRD) Drugs Industry Trends
  2. 2.2 End-Stage Renal Disease (ESRD) Drugs Industry Drivers
  3. 2.3 End-Stage Renal Disease (ESRD) Drugs Industry Opportunities and Challenges
  4. 2.4 End-Stage Renal Disease (ESRD) Drugs Industry Restraints
3 End-Stage Renal Disease (ESRD) Drugs Market by Manufacturers
  1. 3.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global End-Stage Renal Disease (ESRD) Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global End-Stage Renal Disease (ESRD) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global End-Stage Renal Disease (ESRD) Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global End-Stage Renal Disease (ESRD) Drugs Manufacturers, Product Type & Application
  7. 3.7 Global End-Stage Renal Disease (ESRD) Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global End-Stage Renal Disease (ESRD) Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 End-Stage Renal Disease (ESRD) Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 End-Stage Renal Disease (ESRD) Drugs Tier 1, Tier 2, and Tier 3
4 End-Stage Renal Disease (ESRD) Drugs Market by Type
  1. 4.1 End-Stage Renal Disease (ESRD) Drugs Type Introduction
  2. 4.1.1 Sanguinate
  3. 4.1.2 Tesidolumab
  4. 4.1.3 Calcium Succinate
  5. 4.1.4 Mk-3866
  6. 4.1.5 Pacritinib
  7. 4.1.6 Others
  8. 4.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Type
  9. 4.2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Type (2021-2032)
  11. 4.2.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type (2021-2032)
  12. 4.3 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type
  13. 4.3.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Type (2021-2032)
  15. 4.3.3 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Type (2021-2032)
5 End-Stage Renal Disease (ESRD) Drugs Market by Application
  1. 5.1 End-Stage Renal Disease (ESRD) Drugs Application Introduction
  2. 5.1.1 ICU
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.1.4 Others
  6. 5.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Application
  7. 5.2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application
  11. 5.3.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Application (2021-2032)
6 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region
  1. 6.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region
  1. 7.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region
  2. 7.1.1 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032)
  8. 7.2.2 North America End-Stage Renal Disease (ESRD) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032)
  11. 7.3.2 Europe End-Stage Renal Disease (ESRD) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific End-Stage Renal Disease (ESRD) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa End-Stage Renal Disease (ESRD) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG End-Stage Renal Disease (ESRD) Drugs Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Merck & Co Inc
  8. 8.2.1 Merck & Co Inc Company Information
  9. 8.2.2 Merck & Co Inc Business Overview
  10. 8.2.3 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Product Portfolio
  12. 8.2.5 Merck & Co Inc Recent Developments
  13. 8.3 VESSL Therapeutics Ltd
  14. 8.3.1 VESSL Therapeutics Ltd Company Information
  15. 8.3.2 VESSL Therapeutics Ltd Business Overview
  16. 8.3.3 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Product Portfolio
  18. 8.3.5 VESSL Therapeutics Ltd Recent Developments
  19. 8.4 Prolong Pharmaceuticals LLC
  20. 8.4.1 Prolong Pharmaceuticals LLC Company Information
  21. 8.4.2 Prolong Pharmaceuticals LLC Business Overview
  22. 8.4.3 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Product Portfolio
  24. 8.4.5 Prolong Pharmaceuticals LLC Recent Developments
  25. 8.5 CTI BioPharma Corp
  26. 8.5.1 CTI BioPharma Corp Company Information
  27. 8.5.2 CTI BioPharma Corp Business Overview
  28. 8.5.3 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Product Portfolio
  30. 8.5.5 CTI BioPharma Corp Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 End-Stage Renal Disease (ESRD) Drugs Value Chain Analysis
  2. 9.1.1 End-Stage Renal Disease (ESRD) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 End-Stage Renal Disease (ESRD) Drugs Production Mode & Process
  6. 9.2 End-Stage Renal Disease (ESRD) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 End-Stage Renal Disease (ESRD) Drugs Distributors
  9. 9.2.3 End-Stage Renal Disease (ESRD) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst